DLA Piper has advised Chinese pharmaceutical product distributor Sinopharm Group Co on its HK$4 billion ($515 million) H-share placement, while Morrison & Foerster represented the placing agents – China International Capital Corp (CICC), UBS and Morgan Stanley.

Sinopharm will use the net proceeds to fund the expansion of its distribution and retail network.

Hong Kong capital markets partner Charles Chau headed the team for MoFo, while Hong Kong-based partners John Moore and Gregory Wang handled the U.S. aspects of the transaction.

Grandall Law Firm advised Sinopharm on PRC law, while Jiayuan Law Office served as PRC counsel for the placing agents.

Kanishk Verghese is North Asia journalist at ALB. Follow us on Twitter: @ALB_Magazine.

Other related stories:

• DLA transport expert moves to CBP
• MoFo, HSF star in $512 mln Fosun Pharma IPO
• MoFo, Skadden star in $20.1 bln Sprint-Softbank deal